154 related articles for article (PubMed ID: 37208661)
1. Patient-reported outcome (PRO)-based symptom assessment in patients with advanced lung cancer receiving first-line combination immunotherapy: a protocol for a multicenter, prospective, observational study.
Deng Y; Hu H; Jia R; Dai W; Wang D; Zhang P; Zhang P; Cheng K; Tang J; Wen Y; Zhou X; Shi Q; Xiong Z; Zhou J
BMC Pulm Med; 2023 May; 23(1):176. PubMed ID: 37208661
[TBL] [Abstract][Full Text] [Related]
2. Using patient-reported outcomes to manage postoperative symptoms in patients with lung cancer: protocol for a multicentre, randomised controlled trial.
Dai W; Zhang Y; Feng W; Liao X; Mu Y; Zhang R; Wei X; Wu C; Xie S; Li Q; Shi Q
BMJ Open; 2019 Aug; 9(8):e030041. PubMed ID: 31455710
[TBL] [Abstract][Full Text] [Related]
3. Developing and validating utility parameters to establish patient-reported outcome-based perioperative symptom management in patients with lung cancer: a multicentre, prospective, observational cohort study protocol.
Dai W; Xie S; Zhang R; Wei X; Wu C; Zhang Y; Feng W; Liao X; Mu Y; Zhou H; Cheng X; Jiang Y; He J; Li Q; Yang X; Shi Q
BMJ Open; 2019 Oct; 9(10):e030726. PubMed ID: 31662377
[TBL] [Abstract][Full Text] [Related]
4. Application of the patient-reported outcome-based postoperative symptom management model in lung cancer: a multicenter randomized controlled trial protocol.
Liang Y; Jing P; Gu Z; Shang L; Ge P; Zhang Y; Wang L; Qiu C; Zhu X; Tan Z
Trials; 2024 Feb; 25(1):130. PubMed ID: 38365704
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.
Mendoza TR; Hong DS; Peterson CB; Stephen B; Dumbrava E; Pant S; Tsimberidou AM; Yap TA; Sheshadri A; Altan M; George G; Castillo L; Rodriguez E; Gong J; Subbiah V; Janku F; Fu S; Piha-Paul SA; Ahnert JR; Karp DD; Cleeland C; Meric-Bernstam F; Naing A
Sci Rep; 2022 Aug; 12(1):14367. PubMed ID: 35999229
[TBL] [Abstract][Full Text] [Related]
6. Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.
Chen W; Lin J; Yang T; Xin Zhang Z; Tao L; Xiao Z; Chen H; Qi X; Sun L; Cao Y; Lin L
Integr Cancer Ther; 2023; 22():15347354221151147. PubMed ID: 36710490
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal study of symptom burden in outpatients with advanced cancers based on electronic Patient-Reported Outcome (ePRO) platform: a single institution, prospective study protocol.
Tang L; Pang Y; He Y; Shi Q; Han X; Li Z; Zhou C; Zhou Y; He S; Wang Y; Zhang Y; Song L; Wang B; Li X
BMJ Open; 2020 Nov; 10(11):e038223. PubMed ID: 33444183
[TBL] [Abstract][Full Text] [Related]
9. Developing and validating utility parameters to establish patient-reported outcome-based perioperative symptom management in patients undergoing prostatectomy: a multicentre, prospective, observational cohort study protocol.
Li J; Chen T; Gao J; Peng F; Gu T; Jin B
BMJ Open; 2023 Aug; 13(8):e074763. PubMed ID: 37553190
[TBL] [Abstract][Full Text] [Related]
10. Registry study of immune-related adverse events using electronic patient-reported outcome in patients with cancer receiving immune checkpoint inhibitors: protocol for a multicentre cohort study.
Hirata T; Kawaguchi T; Azuma K; Torii A; Usui H; Kim S; Hayama T; Hirate D; Kawahara Y; Kumihashi Y; Chisaka T; Wako T; Yoshimura A; Miyaji T; Yamaguchi T
BMJ Open; 2023 Nov; 13(11):e073724. PubMed ID: 37993166
[TBL] [Abstract][Full Text] [Related]
11. Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings.
Walker MS; Wong W; Ravelo A; Miller PJE; Schwartzberg LS
Clin Lung Cancer; 2018 Mar; 19(2):139-147. PubMed ID: 29103883
[TBL] [Abstract][Full Text] [Related]
12. Monitoring multidimensional aspects of quality of life after cancer immunotherapy: protocol for the international multicentre, observational QUALITOP cohort study.
Vinke PC; Combalia M; de Bock GH; Leyrat C; Spanjaart AM; Dalle S; Gomes da Silva M; Fouda Essongue A; Rabier A; Pannard M; Jalali MS; Elgammal A; Papazoglou M; Hacid MS; Rioufol C; Kersten MJ; van Oijen MG; Suazo-Zepeda E; Malhotra A; Coquery E; Anota A; Preau M; Fauvernier M; Coz E; Puig S; Maucort-Boulch D
BMJ Open; 2023 Apr; 13(4):e069090. PubMed ID: 37105689
[TBL] [Abstract][Full Text] [Related]
13. Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial.
Gao R; Zhang Y; Hou W; Li J; Zhu G; Zhang X; Xu B; Wu Z; Wang H
Trials; 2021 Mar; 22(1):214. PubMed ID: 33731199
[TBL] [Abstract][Full Text] [Related]
14. Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1/PD-L1 therapy.
King-Kallimanis BL; Kanapuru B; Blumenthal GM; Theoret MR; Kluetz PG
Semin Oncol; 2018 Aug; 45(4):201-209. PubMed ID: 30482633
[TBL] [Abstract][Full Text] [Related]
15. What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer.
Whisenant MS; Williams LA; Garcia Gonzalez A; Mendoza T; Shi Q; Cleeland C; Zhang J; Heymach J; Simon G
JCO Oncol Pract; 2020 Oct; 16(10):e1151-e1160. PubMed ID: 32539654
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal patient-reported outcomes 1 year after thoracoscopic segmentectomy versus lobectomy for early-stage lung cancer: a multicentre, prospective cohort study protocol.
Gao X; Dai W; Zhang Q; Liu W; Liu Y; Yang L; Wei X; Shi Q; Pompili C; Pu Y; Xie S; Xiang R; Tian B; Hu B; Yang X; Wang X; Yang X; Xie T; Tang Y; Qiao G; Sun N; Gao S; Zhang G; Chen D; Cui Y; Chen X; He Y; Zhang R; Li Q; Zhuang X
BMJ Open; 2023 Jan; 13(1):e067841. PubMed ID: 36657755
[TBL] [Abstract][Full Text] [Related]
17. Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study.
Shoji F; Yamashita T; Kinoshita F; Takamori S; Fujishita T; Toyozawa R; Ito K; Yamazaki K; Nakashima N; Okamoto T
BMJ Open; 2022 Jun; 12(6):e061674. PubMed ID: 35676015
[TBL] [Abstract][Full Text] [Related]
18. Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study.
Cleeland CS; Mayer M; Dreyer NA; Yim YM; Yu E; Su Z; Mun Y; Sloan JA; Kaufman PA
Breast; 2014 Dec; 23(6):763-9. PubMed ID: 25193423
[TBL] [Abstract][Full Text] [Related]
19. Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39).
Mody GN; Stover AM; Wang M; King-Kallimanis BL; Jansen J; Henson S; Chung AE; Jonsson M; Bennett A; Smith AB; Wood WA; Deal A; Ginos B; Dueck AC; Schrag D; Basch E
Lung Cancer; 2021 Dec; 162():1-8. PubMed ID: 34634754
[TBL] [Abstract][Full Text] [Related]
20. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
Williams LA; Whisenant MS; Mendoza TR; Haq S; Keating KN; Cuffel B; Cleeland CS
Qual Life Res; 2018 Dec; 27(12):3229-3241. PubMed ID: 30187393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
